FREE
Only logged in users are allowed to post comments. Register/ Log in
The Market Oracle is a FREE Financial Markets Forecasting & Analysis web-site.
(c) 2005-2021 MarketOracle.co.uk (Market Oracle Ltd) - Market Oracle Ltd asserts copyright on all articles authored by our editorial team and all comments posted.
Any and all information provided within the web-site, is for general information purposes only and Market Oracle Ltd do not warrant the accuracy, timeliness or suitability of any information provided on this site. nor is or shall be deemed to constitute, financial or any other advice or recommendation by us. and are also not meant to be investment advice or solicitation or recommendation to establish market positions. We do not give investment advice and our comments are an expression of opinion only and should not be construed in any manner whatsoever as recommendations to enter into a market position either stock, option, futures contract, bonds, commodity or any
The Next Marijuana Boom Could Be Even Bigger Than The Last
Published: January 18, 2021
That’s because, despite “Big Pharma’s” massive resources and staggering amounts of spending,
no large pharmaceutical company has ever been able to solve the industry’s most critical problem.
Drug development for major pharmaceutical companies can take as long as a decade.and cost hundreds of billions of dollars in research and development.
Yet a small, little-known company – which could become a truly disruptive cannabis player – now appears uniquely positioned to
upend the drug development market by developing evidence-based cannabis products to combat many of the world’s most serious medical conditions.
Pipeline Review on Hepatitis C Virus Envelope Protein E2 - H2 2020 - ResearchAndMarkets com businesswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businesswire.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
ResearchAndMarkets.com s offering.
COVID-19 continues to be a dominant issue for healthcare systems worldwide and in the United States. The analyst has covered the fields of molecular diagnostics, immunoassays, vaccines and telehealth. These all find themselves both sought-after and challenged during the current COVID-19 crisis. This report provides trending developments, company announcements and analysis from the team on the fast-breaking events in the COVID-19 epidemic.
Particular sections address the most important market changes:
Molecular Diagnostics: COVID-19 has seen the molecular In Vitro diagnostics (IVD) industry bring out its best efforts in terms of fast test RT-PCR tests for their systems, point of care solutions, syndrome tests, high throughput systems and surge production on badly needed kits.